Bedside measurement of hemodynamic biomarkers with fast diffuse correlation spectroscopy

Conference Dates

July 23-26, 2017


The objective assessment and characterization of cerebral tissue health at the bedside is a difficult but highly significant problem in the acute care of strokes and other brain injuries. Observational limitations of current technologies, which are better suited for radiological snapshots rather than continuous monitoring of cerebrovascular health, limit bedside optimization/augmentation of care to subjective judgements of observed neurological deficits. In recent years, Diffuse Correlation Spectroscopy (DCS) has proven to be an increasingly popular non-invasive optical technique to solve this technological gap by directly measuring and monitoring deep tissue blood flow. Here, we highlight DCS’s utility as a clinical bedside monitor of acute CBF changes in patients affected with ischemic stroke. In addition, we highlight the development and application of new ‘fast’ DCS instrument that uses conventional DCS sources/detectors, and optimized software computations to measure blood flow ‘waveforms’ at measurement rates of 50-100 Hz. A direct consequence of this new CBF data type is the ability to characterize potentially chronic biomarkers of cerebral tissue health at the bedside. First

3.pdf (389 kB)

This document is currently not available here.